An Irish pharmaceutical company is now developing a range of drugs that could be used to fight cancer.
Solvotrin Therapeutics, based in Dublin and Cork, is developing a range of Aspirin prodrugs after a study confirmed that Aspirin reduced the risk of several cancers, including breast cancer and lung cancer.
'The CAPP2 clinical study clearly demonstrates that Aspirin can prevent cancer,' Pat O’Flynn, CEO of Solvotrin Therapeutics, told Silicon Republic. 'However, the beneficial effects of Aspirin only became apparent following long-term use of at least three to four years and at high doses of Aspirin.'
'While traditional Aspirin can cause gastrointestinal damage, bleeding and ulcers, even at low doses, Solvotrin’s prodrugs do not cause injury to the stomach and intestines, and there is enormous potential for these drugs in the fight against cancer. New data on our lead prodrug, ST0702, have shown it to be more effective than Aspirin in cancer models,' O’Flynn said.
An Irish research team in the School of Pharmacy and Pharmaceutical Sciences at Trinity College, Dublin originally discovered the range of Aspirin prodrugs Solvotrin Therapeutics is now developing.
Solvotrin Therapeutics has offices in Cork and Dublin.